Leukocyte DNA methylation-based signatures for atherosclerotic cardiovascular disease risk prediction in the Million Veteran Program
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background and Aims
The contribution of DNA methylation signatures to atherosclerotic cardiovascular disease (ASCVD) risk prediction remains unclear. We developed methylation risk scores (MRS) for incident ASCVD and assessed whether they improved risk prediction beyond established risk factors.
Methods
We studied 44,674 Million Veteran Program participants with leukocyte DNA methylation data, divided into two independent subcohorts: a prevalent ASCVD cohort (n=27,560) used for epigenome-wide association analyses (EWAS) to inform cytosine-phosphate-guanine dinucleotide selection, and a cohort free of ASCVD at blood draw (n=17,114), split into training and testing sets for MRS development and evaluation. MRS for incident ASCVD were developed using elastic net regression. Incremental prediction beyond clinical risk factors was assessed by improvement in discrimination (ΔCPE), reclassification (NRI), and calibration.
Results
Three MRS were developed: MRS-1A, informed by prevalent ASCVD EWAS and probe reliability; MRS-1B, informed by EWAS alone; and MRS-2, using an agnostic probe reliability-based approach. Among 17,114 participants (mean [SD] age, 58.9 [14.1] years; 89.6% men; 54.2% European), 2,789 developed ASCVD over a median follow-up of 7.4 years. Each MRS was associated with incident ASCVD (HR per 1-SD: 1.97 [95% CI, 1.72-2.26] for MRS-1A, 2.08 [1.83-2.37] for MRS-1B, and 2.07 [1.78-2.39] for MRS-2) and modestly improved discrimination beyond clinical risk factors (ΔCPE: 0.014 [0.006, 0.021], 0.016 [0.007, 0.023], and 0.013 [0.006, 0.021], respectively). MRS improved risk stratification, driven by the downward reclassification of non-events (non-event NRI: 3.6% [2.6-4.7], 5.4% [4.3-6.5], and 3.6% [2.6-4.6], respectively), while maintaining calibration.
Conclusions
DNA methylation-based signatures were associated with incident ASCVD and modestly improved risk prediction beyond that of traditional risk factors.
Key points
Key Question
Do DNA methylation-based risk scores improve the prediction of incident atherosclerotic cardiovascular disease (ASCVD) beyond the established clinical risk factors?
Key Finding
DNA methylation-based risk scores were strongly associated with incident ASCVD and provided modest but statistically significant improvement in risk prediction beyond traditional clinical risk factors in a primary prevention cohort.
Take-home Message
These findings suggest that leukocyte DNA methylation-based signatures may provide incremental value for ASCVD risk assessment and support the further evaluation of epigenetic biomarkers in multi-omics risk-prediction frameworks.
